Septerna (SEPN) Insider Shalini Sharp Buys 15,000 Shares

Shalini Sharp, an insider at Septerna, Inc., acquired 15,000 shares of the company on June 26, 2026. This transaction is notable for its size, but details about the purchase price and total value were not disclosed. Shares of Septerna, which trade on the NasdaqGM under the ticker SEPN, were priced at $34.75 on Wednesday.

Other Institutional Activity in Septerna, Inc.

Among Septerna's institutional investors, RA Capital Management, L.P. maintained its position with 6,995,858 shares, valued at about $168.1 million. TRV GP V, LLC also held steady with 6,215,591 shares worth approximately $149.4 million. Driehaus Capital Management LLC reduced its stake by 413,898 shares, now holding 4,395,572 shares valued at $105.6 million, an 8.6% decrease. Goldman Sachs Group Inc. increased its holdings by 191,298 shares, bringing its total to 2,906,427 shares valued at around $69.8 million, representing a 7.0% increase.

Septerna, Inc. Stock Down 13.4%

Shares of Septerna, Inc. traded near $34.75 on Wednesday. The biotechnology company, with a market cap of approximately $1.68 billion, has a 52-week trading range between $10.30 and $37.99. Its 50-day moving average is $28.91, while the 200-day moving average stands at $25.31. Septerna has a strong liquidity position with a current ratio of 4.71 and a quick ratio of 4.63, but it carries some debt, with a debt-to-equity ratio of 6.10.

Recent Earnings

Septerna reported revenue of $72.3 million, experiencing a robust 120.11% growth. However, the company posted a net margin of -49.88% and a return on equity of -9.26%. Earnings per share were -$0.80, reflecting its unprofitable status. The next earnings release is scheduled for August 10, 2026.

Insider Buying and Selling at Septerna, Inc.

In addition to Shalini Sharp's purchase, several other insiders were active. Samira Shaikhly, Chief People Officer, sold 2,178 shares at $35.18 on June 29, 2026, under a planned transaction. She also bought 2,178 shares at $6.81 on the same day. Bernard Coulie and Alan Ezekowitz each bought 15,000 shares on June 26, 2026.

Analysts Set New Price Targets

On June 8, 2026, Raymond James maintained its buy rating for Septerna with a price target of $53.00. JP Morgan and Truist Securities also maintained buy ratings earlier in the year, with targets of $38.00 and $35.00, respectively. Overall, analysts have a strong buy consensus on Septerna, with a target mean price of $45.78 based on nine opinions.

About Septerna, Inc.

Septerna, Inc. is a biotechnology company based in South San Francisco, California. It focuses on discovering and developing G protein-coupled receptor (GPCR) oral small molecule products for treating various diseases, including endocrinology, immunology, inflammation, and metabolic disorders. The company is known for its PTH1R Program targeting hypoparathyroidism and has a collaboration with Novo Nordisk.

Bottom Line

Shalini Sharp's purchase of 15,000 shares highlights insider interest in Septerna, Inc. Investors keep an eye on such transactions for potential insights into company prospects. Septerna's shares, trading near their 52-week high, reflect market interest, while analysts' strong buy ratings suggest positive sentiment. Remember, insider transactions are disclosed after the fact and do not necessarily indicate future performance.